Compare Vaginal Estrogen and Platelet-rich Plasma Over Women With Genitourinary Syndrome of Menopause

Condition(s) studied

Investigational drug(s) / intervention(s)

Vaginal estrogen supplement: Daily vaginal estrogen supplement, then twice per week. Continue for three months.

Platelet-rich plasma injection: Monthly platelet-rich plasma injection for three months

Study summary

The definition of Genitourinary Syndrome of Menopause (GSM) is the decline of estrogens during menopause results in symptoms and clinical signs from both systems. Estrogen and other hormones production decrease after menopause because the ovaries lose their effectiveness, leading to mucosal atrophy, reduced vaginal moisture, dysuria, urgency, recurrent infection, burning, pruritus and dyspareunia.

The treatment included vaginal estrogen supplement, vaginal hyaluronic acid supplement, vaginal laser, platelet rich plasma, etc. Observational cohort study will be used for study design, and questionnaire, pelvic examination, vaginal pap smear with maturation index (MI), vaginal pH, and other methods will be used for evaluation of the effectiveness and side effects.

Eligibility

Primary outcome measure(s)

• Visual analogue scale (VAS) — 2022/8/10-2024/2/28
  Changes in GSM symptoms include vaginal dryness, dyspareunia, itching, burning, dysuria
• Vaginal health index score (VHIS) — 2022/8/10-2024/2/28
  One of the most commonly used scores for the evaluation of vaginal elasticity, secretions, pH, the presence of petechiae on the epithelial mucosa, and hydration
• Female Sexual Function Index (FSFI) — 2022/8/10-2024/2/28
  A brief multidimensional scale for assessing sexual function in women.

Trial sites (1)

More Mackay Memorial Hospital trials in Taiwan

Other trials for the same condition